Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 155

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 10
Chunk 155
---
 outstanding options to purchase 27,000 shares.

(3)As of December 31, 2024, Dr. Guerard holds outstanding options to purchase 81,468 shares.

(4)As of December 31, 2024, Mr. McCollum holds outstanding options to purchase 27,000 shares.

(5)As of December 31, 2024, Ms. Thunen holds outstanding options to purchase 27,000 shares.

(6)As of December 31, 2024, Dr. Scheiner holds outstanding options to purchase 27,000 shares.

(7)Resigned from the board of directors on March 21, 2024, effective as of the effective time of the Merger.

(8)Dr. Porteus received compensation from Graphite under a consulting agreement.

Insider Trading Policy

We have adopted an insider trading policy governing the purchase, sale, and/or other dispositions of our securities and those of public companies in which we have a business relationship by our directors, executive officers, employees and independent contractors, contingent workers and consultants, that we believe is reasonably designed to promote compliance 

136

Table of Contents

with insider trading laws, rules and regulations, and the exchange listing standards applicable to us. It is our policy that any transactions in LENZ securities by the company itself shall be in full compliance with insider trading laws, rules and regulations. A copy of our insider trading policy, including any amendments thereto, is filed as Exhibit 19.1 to this Annual Report on Form 10-K.